NVAX
Novavax Inc
10.60$
+0.5%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 448.4% | 51.1% | 52.0% | 11.1% | 71.7% | 41.5% | 2.1% | 5.9% | 30.5% | 17.1% | 22.0% | 25.1% | 22.1% | |
| -348.4% | 48.9% | 48.0% | 88.9% | 28.3% | 58.5% | 97.9% | 94.1% | 69.5% | 82.9% | 78.0% | 74.9% | 77.9% | |
| 481.5% | 56.5% | 98.7% | 25.7% | 103.1% | 118.2% | 13.3% | 32.4% | 139.5% | 50.3% | 68.4% | 124.7% | 81.8% | |
| 487.0% | 53.3% | 92.5% | 24.4% | 83.7% | 88.7% | 7.2% | 18.2% | 44.9% | 23.2% | 20.6% | 47.0% | 29.3% | |
| 221.0% | 111.9% | 195.8% | 50.1% | 186.9% | 206.9% | 20.6% | 49.9% | 322.2% | 68.6% | 89.1% | 171.7% | 132.8% | |
| -569.4% | -63.0% | -147.8% | 38.7% | -158.6% | -148.4% | 77.3% | 44.2% | -252.7% | 14.3% | -11.1% | -96.8% | -54.9% | |
| 13.0% | 1.4% | 4.4% | 1.0% | 5.0% | 8.6% | 0.9% | 2.3% | 7.8% | 4.0% | 3.5% | 10.0% | 5.3% | |
| -595.9% | -60.7% | -154.8% | 39.6% | -144.8% | -83.3% | 78.0% | 44.9% | -288.2% | 12.2% | -6.1% | -91.1% | -59.3% | |
| -3.2% | 0.6% | 2.4% | 0.5% | -1.2% | 8.4% | 0.2% | 0.4% | -0.9% | 0.3% | 0.7% | 3.0% | 0.6% | |
| -592.7% | -61.2% | -157.2% | 39.1% | -143.5% | -91.8% | 77.8% | 44.5% | -287.3% | 11.9% | -6.8% | -94.2% | -59.9% | |
| -531.6% | -55.5% | -137.5% | 43.3% | -124.7% | -60.6% | 80.1% | 50.4% | -271.1% | 19.6% | -0.4% | -70.3% | -48.9% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.